Rubric Capital Management LP Kiniksa Pharmaceuticals, Ltd. Transaction History

Rubric Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$17.63 - $21.74 $12.5 Million - $15.5 Million	-711,492 Reduced 24.47%	2,196,009 $43.3 Million
Q4 2023 Feb 13, 2024	SELL	$14.37 - $19.07 $2.44 Million - $3.24 Million	-169,948 Reduced 5.52%	2,907,501 $51 Million
Q3 2023 Nov 14, 2023	SELL	$13.62 - $20.2 $4.1 Million - $6.07 Million	-300,715 Reduced 8.9%	3,077,449 $53.5 Million
Q2 2023 Aug 11, 2023	BUY	$10.44 - $16.48 $6.29 Million - $9.93 Million	602,528 Added 21.71%	3,378,164 $47.6 Million
Q1 2023 May 12, 2023	BUY	$10.7 - $15.79 $12.9 Million - $19 Million	1,206,133 Added 76.85%	2,775,636 $29.9 Million
Q4 2022 Feb 10, 2023	BUY	$11.42 - $17.05 $1.41 Million - $2.1 Million	123,396 Added 8.53%	1,569,503 $23.5 Million
Q3 2022 Nov 14, 2022	BUY	$9.76 - $13.41 $9 Million - $12.4 Million	922,579 Added 176.22%	1,446,107 $18.6 Million
Q2 2022 Aug 15, 2022	BUY	$7.6 - $11.41 $3.98 Million - $5.97 Million	523,528 New	523,528 $5.07 Million
Q4 2021 Feb 14, 2022	SELL	$10.39 - $15.15 $1.6 Million - $2.33 Million	-153,618 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$11.39 - $16.23 $1.75 Million - $2.49 Million	153,618 New	153,618 $1.75 Million

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $710M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Rubric Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rubric Capital Management LP with notifications on news.